Page 11 - Crispr News Today

From the first licensed CRISPR medicine to unprecedented climate migration, these are the top 10 news stories of 2023 that have profound implications for the future.

FDA approves 1st CRISPR gene therapy to treat sickle cell disease. Nine hospitals have been authorized to offer the one-time treatment by Vertex Pharmaceuticals

Presenters at the American Society of Hematology Annual Meeting and Exposition agreed that novel strategies, such as CRISPR and base editing, have potential to fine-tune the latest immunotherapy advancements to increase the efficacy and durability of a range of treatments.

Both Vertex Pharmaceuticals Inc.’s Casgevy (exagamglogene autotemcel, exa-cel) and Bluebird Bio Inc.’s Lyfgenia (lovotibeglogene autotemcel, lovo-cel) received U.S. FDA approval Dec. 8, providing 16,000 American sickle cell patients who have recurring vaso-occlusive events with access to the first cell-based gene therapies.

The Food and Drug Administration is expected to approve a new gene editing therapy for sickle cell disease, its first green light for a Crispr treatment.

Kath Mackay discussed the need for a new industrial strategy to boost growth across strategic growth sectors in the UK.

The Food and Drug Administration approved a new gene editing therapy for sickle cell disease, its first green light for a Crispr treatment.

Sickle cell disease is a painful, inherited blood disorder that can be debilitating and lead to premature death

The U.S. FDA on Friday approved two gene therapies for sickle cell disease from Vertex Pharmaceuticals and CRISPR Therapeutics, as well as from bluebird bio.

The Food and Drug Administration has approved the world's first medicine employing CRISPR gene-editing technology to treat sickle cell disease, giving thousands new hope to treat the painful disease.